logo

Lexicon Pharmaceuticals Inc. (LXRX)



Trade LXRX now with
  Date
  Headline
3/25/2019 7:26:22 AM Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) FY20 Rev. Estimate To 98.3 M From 126.8 M
3/25/2019 7:26:09 AM Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) Q4 20 Rev. Estimate To 31.8 M From 41.8 M
3/25/2019 7:25:54 AM Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) Q3 20 Rev. Estimate To 25.8 M From 33.6 M
3/25/2019 7:25:39 AM Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) Q2 20 Rev. Estimate To 21.2 M From 27.2 M
3/25/2019 7:25:24 AM Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) Q1 20 Rev. Estimate To 19.5 M From 24.2 M
3/25/2019 7:25:10 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) FY19 Rev. Estimate To 71.0 M From 77.1 M
3/25/2019 7:24:54 AM Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) Q4 19 Rev. Estimate To 19.3 M From 22.8 M
3/25/2019 7:24:33 AM Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) Q3 19 Rev. Estimate To 18.2 M From 20.8 M
3/25/2019 7:01:56 AM Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) FY20 Estimate To -1.60 From -0.85
3/25/2019 7:01:37 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) Q4 20 Estimate To -0.36 From -0.11
3/25/2019 7:01:24 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) Q3 20 Estimate To -0.39 From -0.16
3/25/2019 7:00:52 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) Q2 20 Estimate To -0.41 From -0.19
3/25/2019 7:00:19 AM Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) Q1 20 Estimate To -0.43 From -0.39
3/25/2019 7:00:00 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) FY19 Estimate To -0.95 From -0.90
3/25/2019 6:59:42 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) Q4 19 Estimate To -0.30 From -0.27
3/25/2019 6:59:28 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) Q3 19 Estimate To -0.25 From -0.23
3/25/2019 6:58:59 AM Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Outperform With $34 Down From $38 Price Target
3/15/2019 12:54:04 PM Lexicon Announces Dosing Of First Patient In TELE-ABC Study, Phase 2a Study Of Telotristat Ethyl In Biliary Tract Cancer
3/13/2019 7:22:23 AM Lexicon Q4 Net Loss $16.8 Mln Or $0.16/Shr
3/4/2019 6:57:09 AM Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) FY19 Rev. Estimate To 74.9 M From 74.8 M